(NASDAQ: SPRO) Spero Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 6.45%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 54.68%.
Spero Therapeutics's earnings in 2025 is -$53,601,000.On average, 1 Wall Street analyst forecast SPRO's earnings for 2025 to be -$80,473,572, with the lowest SPRO earnings forecast at -$80,473,572, and the highest SPRO earnings forecast at -$80,473,572.
In 2026, SPRO is forecast to generate -$64,716,509 in earnings, with the lowest earnings forecast at -$64,716,509 and the highest earnings forecast at -$64,716,509.